Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
Official Full Name
Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant)
Synonyms
Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin
Squence
Amino Acid Sequence
MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F
Synonyms
Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin
Accession
Gene ID
Summary
The clinical use of the potent antitumor activity of TNF-alphahas been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-alphamutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-alpha, which binds to the murine TNF-R55 but not to the murine TNF-R75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-alpha, which binds to both murine TNF receptors. Based on these results, many TNF-alphamutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.
Source
Escherichia coli.
Molecular Weight
Approximately 16.9 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, rHuTNF-α Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg in the presence of actinomycin D.
Appearance
Sterile filtered white lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0.
Endotoxin
Less than 1 EU/ug of rHu TNF-α/TNFSF2, Variant as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
Purity
> 98 % by SDS-PAGE and HPLC analyses.
SDS-PAGE
Pack Size
10ug/100ug/500ug
Safety Data Sheet (SDS) Download
Technical Data Sheet (TDS) Download
Links
This product is branded by ChemWhat and sold through our website and here is the corresponding link Recombinant Human Tumor Necrosis Factor-alpha/TNFSF2, Variant (rHuTNF-alpha/TNFSF2,Variant) on ChemWhat
